Review
Oncology
J. Tobias, E. Garner-Spitzer, M. Drinic, U. Wiedermann
Summary: Immunotherapy has revolutionized cancer treatment, with a focus on breast cancer. Traditional treatment methods have limitations, but tumor vaccines may offer a potential solution. This review discusses peptide-based Her-2 / neu vaccines and their evaluation in clinical settings.
Article
Oncology
Joshua Tobias, Mirjana Drinic, Sandra Hoegler, Katharina Ambroz, Karin Baier, Petra Kodajova, Erwin Tomasich, Anna S. Berghoff, Anna Schmid, Erika Garner-Spitzer, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Ursula Wiedermann
Summary: The combination of Her-2/neu vaccine and multi-peptide vaccine can reduce lung metastases and may prevent tumor recurrence and spread. Additionally, combination therapy targeting PD-L1 may result in complete remission of metastases.
TRANSLATIONAL ONCOLOGY
(2022)
Review
Oncology
Nicholas J. J. Ede, Anthony J. J. Good, Joshua Tobias, Erika Garner-Spitzer, Christoph C. C. Zielinski, Ursula Wiedermann
Summary: Her-2/neu is a tumor-associated protein associated with the development of aggressive cancers. HER-Vaxx, a B cell vaccine, shows potential for the treatment of gastric cancer by inducing the production of antibodies. Preclinical studies demonstrate the safety and efficacy of this vaccine.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Patrick M. McCarthy, G. Travis Clifton, Timothy J. Vreeland, Alexandra M. Adams, Anne E. O'Shea, George E. Peoples
Summary: HER2 is a prevalent growth factor in malignancies, with over-expression linked to poor survival. The novel AE37 vaccine, based on HER2, shows potential in breast and prostate cancer clinical trials. Future trials may expand the use of AE37 in treating other HER2-expressing malignancies.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Review
Oncology
Yihan Zhou
Summary: Constituting 15 to 20% of breast cancer cases, the triple-negative subtype lacks effective hormone-associated therapies. A more powerful immunotherapeutic vaccination incorporating HER2/neu antigens has shown promising results in clinical trials, especially in the triple-negative population. The combination of HER2/neu-based vaccines with GM-CSF immunoadjuvants and targeted drugs has the potential to further enhance the efficacy of breast cancer treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biology
Manaswini Jagadeb, Kali Prasad Pattanaik, Surya Narayan Rath, Avinash Sonawane
Summary: The study identified potential peptide-based vaccine targets against tuberculosis using an immune-informatics approach. By analyzing the Mtb proteome, two potential vaccine candidates were selected, showing the ability to induce protective immune responses. The peptides exhibited strong binding affinity and antigenic properties, suggesting their potential as vaccine candidates against TB.
COMPUTERS IN BIOLOGY AND MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Mahdi Dehghan-Manshadi, Amin Reza Nikpoor, Hossein Hadinedoushan, Fateme Zare, Mojtaba Sankian, Farzaneh Fesahat, Mohammad Taher Tahoori, Mahmoud Reza Jaafari, Houshang Rafatpanah
Summary: The study compared the prophylactic effects of vaccines based on dendritic cells (DCs) and peripheral blood mononuclear cells (PBMCs) in a mouse model of breast cancer. It was found that the PBMC-based vaccine was more effective in enhancing protective immune responses, making it a simpler and more cost-effective candidate vaccine compared to DC-based vaccines.
BIOCHEMISTRY AND CELL BIOLOGY
(2021)
Article
Immunology
Tracer Yong, Ko-Keng Chang, Yi-Sheng Wang, Che Ma
Summary: This article introduces the preparation and clinical application of a cancer vaccine targeting IL-17RB. The vaccine is composed of multiple synthesized epitope peptides chemically conjugated onto CRM197, a carrier protein, and has a durable anti-cancer effect.
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Nastaran Barati, Fatemeh Mosaffa, Atefeh Razazan, Ali Badiee, Javad Behravan, Amin Reza Nikpoor, Seyed Mousa Motavallihaghi, Mahmoud Reza Jaafari
Summary: The study focuses on developing a nanoliposomal vaccine for HER2-overexpressing breast cancer to evaluate its immunotherapeutic effects. The findings demonstrate that the formulation is capable of eliciting CD8(+) and CD4(+) responses, inducing the synthesis of cytokines.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Immunology
Yuri Poluektov, Marybeth George, Pirouz Daftarian, Marc C. Delcommenne
Summary: The study focuses on evaluating the binding affinities of SARS-CoV-2 peptides to different MHC alleles using the QuickSwitchTM platform, identifying multiple MHC binders with high promiscuity. These results provide important data for further research on the SARS-CoV-2 virus and its antigenic epitopes.
Article
Immunology
Shinji Morisaki, Hideya Onishi, Takafumi Morisaki, Makoto Kubo, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Sachiko Yoshimura, Poh Yin Yew, Kazuma Kiyotani, Yusuke Nakamura, Masafumi Nakamura, Takanari Kitazono, Takashi Morisaki
Summary: Through analysis of four patients, we found that intranodal vaccination with hybrid neoantigen-pulsed DCs successfully induced a strong immune response and provided insight into the mechanisms of action, suggesting future directions in neoantigen vaccine design.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Instruments & Instrumentation
Saeedeh Khazaei, Ruben Varela-Calvino, Mazda Rad-Malekshahi, Federico Quattrini, Safura Jokar, Nima Rezaei, Saeed Balalaie, Ismaeil Haririan, Noemi Csaba, Marcos Garcia-Fuentes
Summary: This study focused on integrating peptide epitopes into self-assembling materials to develop nanovaccines with high antigen density and improved efficacy. The researchers successfully designed and formulated peptide/polymer hybrid nanoparticles containing MAGE-A3/PADRE epitopes. These nanoparticles showed good compatibility with human cells and triggered immune responses, particularly activating CD8+ cells. In vivo results from vaccinated mice demonstrated specific responses mediated through cellular pathways. Therefore, this research highlights the potential of self-assembled peptide-polymer hybrid nanostructures in enhancing the immunogenicity of peptide epitope vaccines.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Immunology
Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
Summary: This study conducted a clinical trial on transmission blocking vaccines targeting the sexual-stages of the malaria parasite, using two recombinant viral vectored vaccines encoding Pfs25-IMX313 in healthy malaria-naive adults. While the vaccines were immunogenic, they showed weak transmission reducing activity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ziqi Chen, Martin Renqiang Min, Xia Ning
Summary: In this study, two allele-specific Convolutional Neural Network-based methods were developed to predict peptide-MHC binding, achieving more accurate binding peptide prioritization and important amino acid identification. Experimental results demonstrated significant improvement over state-of-the-art methods, with an average percentage improvement of 6.70% on AUC and 17.10% on ROC5 across 128 alleles.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)